7rd4: Difference between revisions
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
The | ==Crystal structure of PfCSP peptide 21 with vaccine-elicited human anti-malaria antibody m43.149== | ||
<StructureSection load='7rd4' size='340' side='right'caption='[[7rd4]], [[Resolution|resolution]] 1.75Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[7rd4]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus] and [https://en.wikipedia.org/wiki/Plasmodium_falciparum Plasmodium falciparum]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7RD4 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7RD4 FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.75Å</td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7rd4 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7rd4 OCA], [https://pdbe.org/7rd4 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7rd4 RCSB], [https://www.ebi.ac.uk/pdbsum/7rd4 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7rd4 ProSAT]</span></td></tr> | |||
</table> | |||
== Function == | |||
[https://www.uniprot.org/uniprot/CSP_PLAFA CSP_PLAFA] The circumsporozoite protein is the immunodominant surface antigen on the sporozoite (the infective stage of the malaria parasite that is transmitted from the mosquito to the vertebrate host). | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Repeat antigens, such as the Plasmodium falciparum circumsporozoite protein (PfCSP), use both sequence degeneracy and structural diversity to evade the immune response. A few PfCSP-directed antibodies have been identified that are effective at preventing malaria infection, including CIS43, but how these repeat-targeting antibodies might be improved has been unclear. Here, we engineered a humanized mouse model in which B cells expressed inferred human germline CIS43 (iGL-CIS43) B cell receptors and used both vaccination and bioinformatic analysis to obtain variant CIS43 antibodies with improved protective capacity. One such antibody, iGL-CIS43.D3, was significantly more potent than the current best-in-class PfCSP-directed antibody. We found that vaccination with a junctional epitope peptide was more effective than full-length PfCSP at recruiting iGL-CIS43 B cells to germinal centers. Structure-function analysis revealed multiple somatic hypermutations that combinatorically improved protection. This mouse model can thus be used to understand vaccine immunogens and to develop highly potent anti-malarial antibodies. | |||
Vaccination in a humanized mouse model elicits highly protective PfCSP-targeting anti-malarial antibodies.,Kratochvil S, Shen CH, Lin YC, Xu K, Nair U, Da Silva Pereira L, Tripathi P, Arnold J, Chuang GY, Melzi E, Schon A, Zhang B, Dillon M, Bonilla B, Flynn BJ, Kirsch KH, Kisalu NK, Kiyuka PK, Liu T, Ou L, Pancera M, Rawi R, Reveiz M, Seignon K, Wang LT, Waring MT, Warner J, Yang Y, Francica JR, Idris AH, Seder RA, Kwong PD, Batista FD Immunity. 2021 Dec 14;54(12):2859-2876.e7. doi: 10.1016/j.immuni.2021.10.017. , Epub 2021 Nov 16. PMID:34788599<ref>PMID:34788599</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
[[Category: Kwong | <div class="pdbe-citations 7rd4" style="background-color:#fffaf0;"></div> | ||
[[Category: Xu | |||
==See Also== | |||
*[[Monoclonal Antibodies 3D structures|Monoclonal Antibodies 3D structures]] | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Large Structures]] | |||
[[Category: Mus musculus]] | |||
[[Category: Plasmodium falciparum]] | |||
[[Category: Kwong PD]] | |||
[[Category: Xu K]] | |||
Latest revision as of 19:28, 18 October 2023
Crystal structure of PfCSP peptide 21 with vaccine-elicited human anti-malaria antibody m43.149Crystal structure of PfCSP peptide 21 with vaccine-elicited human anti-malaria antibody m43.149
Structural highlights
FunctionCSP_PLAFA The circumsporozoite protein is the immunodominant surface antigen on the sporozoite (the infective stage of the malaria parasite that is transmitted from the mosquito to the vertebrate host). Publication Abstract from PubMedRepeat antigens, such as the Plasmodium falciparum circumsporozoite protein (PfCSP), use both sequence degeneracy and structural diversity to evade the immune response. A few PfCSP-directed antibodies have been identified that are effective at preventing malaria infection, including CIS43, but how these repeat-targeting antibodies might be improved has been unclear. Here, we engineered a humanized mouse model in which B cells expressed inferred human germline CIS43 (iGL-CIS43) B cell receptors and used both vaccination and bioinformatic analysis to obtain variant CIS43 antibodies with improved protective capacity. One such antibody, iGL-CIS43.D3, was significantly more potent than the current best-in-class PfCSP-directed antibody. We found that vaccination with a junctional epitope peptide was more effective than full-length PfCSP at recruiting iGL-CIS43 B cells to germinal centers. Structure-function analysis revealed multiple somatic hypermutations that combinatorically improved protection. This mouse model can thus be used to understand vaccine immunogens and to develop highly potent anti-malarial antibodies. Vaccination in a humanized mouse model elicits highly protective PfCSP-targeting anti-malarial antibodies.,Kratochvil S, Shen CH, Lin YC, Xu K, Nair U, Da Silva Pereira L, Tripathi P, Arnold J, Chuang GY, Melzi E, Schon A, Zhang B, Dillon M, Bonilla B, Flynn BJ, Kirsch KH, Kisalu NK, Kiyuka PK, Liu T, Ou L, Pancera M, Rawi R, Reveiz M, Seignon K, Wang LT, Waring MT, Warner J, Yang Y, Francica JR, Idris AH, Seder RA, Kwong PD, Batista FD Immunity. 2021 Dec 14;54(12):2859-2876.e7. doi: 10.1016/j.immuni.2021.10.017. , Epub 2021 Nov 16. PMID:34788599[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||